Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for Caplyta (lumateperone) for Specific Patient Populations

Caplyta label now includes dosage recommendations for specific patient populations; those with moderate or severe hepatic impairment and patients who are concomitantly taking moderate or strong CYP3A4 inhibitors. NEW YORK, April 25, 2022 (GLOBE...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news